# Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

> **NCT03972722** · PHASE2 · UNKNOWN · sponsor: **Guangzhou Gloria Biosciences Co., Ltd.** · enrollment: 89 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** GLS-010

## Key facts

- **NCT ID:** NCT03972722
- **Lead sponsor:** Guangzhou Gloria Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-15
- **Primary completion:** 2022-05-15
- **Final completion:** 2023-05-15
- **Target enrollment:** 89 (ESTIMATED)
- **Last updated:** 2019-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03972722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03972722, "Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03972722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*